Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data
The DOI matches its Crossref record.
Abstract
4037 Background: Response to epidermal growth factor receptor (EGFR) inhibitor, cetuximab appears to correlate with the intensity of the associated skin reaction. This randomized study investigated cetuximab dose-escalation in patients (pts) with EGFR-expressing mCRC failing irinotecan-including therapy (I). Methods: Pts were randomized 22 days after starting cetuximab (400 mg/m 2 initial dose then 250 mg/m 2/week [w]) with I (180 mg/m 2 q 2 w) if they had not experienced >grade (G) 1 skin reaction, any other >G 2 cetuximab-related adverse event and were tolerant to I. Randomization was to standard cetuximab dose (Arm A; 250 mg/m 2/w) or dose-escalation (Arm B; cetuximab dose increased by 50 mg/m 2 q 2 w, until >G 2 toxicity, tumor response or dose = 500 mg/m 2). Pts not randomized (Arm C) continued on standard cetuximab dose. Primary endpoint was to compare in skin and tumor biopsies, taken before and during treatment, the effects of dose-escalation on EGFR and downstream signalling markers with those of the standard cetuximab regimen. Secondary endpoints were PK, efficacy, safety, tolerability, biomarker analyses on tumor biopsies and plasma samples. Results: 284 pts screened, 221 pts EGFR-expressing, 166 pts enrolled and randomized: 45 to Arm A; 44 to Arm B. 77 non-randomized pts were included in Arm C. M/F 106/60, median age 60 years [25–79], median KPS 90 [70–100]. 24 pts in Arm B reached 500 mg/m 2/w. By the cut-off date of July 31 st 2006 the preliminary response rate (RR) in Arm B was 30% vs. 13% in Arm A. RR in arm C was 22%. Preliminary progression-free survival in Arm A was 3,9 mo vs. 4,8 mo in Arm B and 3,9 mo in Arm C. In Arm B, 9% pts had G 3/4 skin reactions, 0% in Arm A (14% in Arm C). Dose related increases in C max and AUC were observed. T 1/2 values were dose independent. Conclusions: Cetuximab dose- escalation up to 500 mg/m 2/w improves RR in pts with no or slight skin reactions on standard dose treatment. Overall cetuximab PK behavior is in good agreement with previous experience. Treatment was generally well tolerated. PD and biomarker results will be presented at the meeting. No significant financial relationships to disclose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lièvre, A., Bachet, J.-B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,444
De Roock, W., Jonker, D. J., Di Nicolantonio, F., Sartore-Bianchi, A., Tu, D., Siena, S., Lamba, S., Arena, S., Frattini, M., Piessevaux, H., et al. (2010) · JAMA · doi:10.1001/jama.2010.1535 · Cited by 748
Self-citationDouillard, J. Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu141 · Cited by 606
Self-citationSiena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J., & Bardelli, A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp280 · Cited by 429
Prognostic versus predictive value of biomarkers in oncology
Oldenhuis, C. N. A. M., Oosting, S. F., Gietema, J. A., & de Vries, E. G. E. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.03.006 · Cited by 349
Metadata
- Authors
- Tejpar, S., Peeters, M., Humblet, Y., Gelderblom, H., Vermorken, J., Viret, F., Glimelius, B., Ciardiello, F., Kisker, O., & Van Cutsem, E.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-06-20
- Volume
- 25
- Issue
- 18_suppl
- Pages
- 4037-4037
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2245406219
- Cited by
- 116
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data. https://app.cochat.ai/papers/10.1200/jco.2007.25.18_suppl.4037
- The paper
- Tejpar, S., Peeters, M., Humblet, Y., Gelderblom, H., Vermorken, J., Viret, F., Glimelius, B., Ciardiello, F., Kisker, O., & Van Cutsem, E. (2007). Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.25.18_suppl.4037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.